Ingeborg Neumann

Managing Partner

Ingeborg Neumann is co-founder and Managing Director of Peppermint VenturePartners GmbH (PVP). She is also Managing Partner of Peppermint Charité Biomedical Fund.

In 1997, Ingeborg Neumann established the Peppermint Holding GmbH, which is a medium-sized industrial group based in Berlin. The Peppermint Group develops and produces high-end, innovative textiles for the fields of fashion, home textiles and technical textiles, with a staff of more than 750 employees, achieving worldwide sales of approx. EUR 90 million.

In addition, Ingeborg Neumann started up the first Peppermint Venture Capital Fund in the year 2000.

What’s more, Ingeborg Neumann serves on several supervisory boards and advisory committees;
e.g. German Textile + Fashion Confederation (President) and Federation of German industries (Vice President and Treasurer).

Ingeborg Neumann studied business economics in Münster and Munich. She has a degree in business and the German title of “Diplom-Kauffrau”.

Past Investments

Exits only

• Scienion AG
• CellAct Pharma GmbH

Dr. Joachim Rautter

Managing Partner

Dr. Joachim Rautter is a co-founder and Managing Director of Peppermint VenturePartners GmbH and Managing Partner of the Peppermint Charité Biomedical Fund.

Prior to the launch of Peppermint VenturePartners, he was Investment Director at Peppermint Holding GmbH. There he was responsible for the investment activities of the Peppermint Venture Capital Fund (VC 1). He has more than 20 years of experience in the venture capital industry and was Chairman of the Supervisory Board of Scienion AG, as well as Chairman of the Advisory Board of JADO Technologies GmbH and Innolume GmbH and also served on the Board of CAP-CMV GmbH. He is currently Chairman of the Board of CEVEC Pharmaceuticals GmbH, CellAct Pharma GmbH and Labforward GmbH as well as a Board Member of CryoTherapeutics SA.

Prior to joining Peppermint, he guided innovative start-ups in the field of start-up financing and entrepreneurial development. In addition, he was involved in key functions in the design and implementation of regional innovation strategies such as BioTOP Berlin-Brandenburg and the innovation concept of the German state of Brandenburg.

Joachim Rautter has a degree in physics and completed his PhD at the Max Volmer Institute for Biophysical Chemistry at the Technical University of Berlin.

Portfolio CBF-1

• CEVEC Pharmaceuticals GmbH
• CryoTherapeutics SA
• Labforward GmbH

Past Investments

Trade Sales

• Scienion AG
• CellAct Pharma GmbH

Dr. Klaus Stöckemann

Managing Partner

Klaus Stöckemann is co-founder and Managing Partner of Peppermint VenturePartners GmbH (PVP).

Prior to launching PVP, Klaus Stöckemann was general partner in the international healthcare venture team of 3i plc, an international Private Equity firm based in London. During his time at 3i he was responsible for more than 12 investments in Europe and the US. His track record includes not only the IPOs of Epigenomics, Jerini and Santhera, but also successful trade sales of Amaxa, Elbion and Evotec Neuroscience.

Before his tenure at 3i, he held leading positions in research and business development at Schering AG (now Bayer) and Asta Medica (a former Degussa-Hüls group subsidiary).

Klaus Stöckemann has been a member of the supervisory boards of Combinature, Epigenomics, Jerini, Amaxa, and Immatics, as well as IntelliDx and Zonare in the US. He is currently chairman of the boards of Emperra and Caterna as well as vice-Chairman of Implandata and board member at Humedics.

He has been an experienced venture capital investor for more than 20 years and was on the board of the German Venture Capital association (BVK from 2015-2020) working with politicians to improve the Venture Capital environment in Germany.

He holds a Ph.D in biology and pharmacology from the University of Mainz, as well as an MBA from WHU/Kellogg, Northwestern University in the United States.

Portfolio CBF-1

• Emperra GmbH E-Health Technologies
• Implandata Ophtalmic Products GmbH
• Caterna Vision GmbH
• Humedics GmbH

Past Investments

IPOs

• Epigenomics
• Jerini
• Santhera

Trade Sales

• Elbion
• Amaxa
• Evotec Neuroscience
• Imtec
• Zonare

M&A

• Combinature

Dr. Magnus Holm

Venture Partner

Dr. Magnus Holm has fortified Peppermint’s investment team as a venture partner since September 2012.

Holm has many years of operative experience in various executive positions in the medical technology industry. In addition to the development and clinical approval of novel innovative medical products, his duties have included business development, sales and marketing and senior business management.

As General Manager for companies such as Biosense Webster, EMEA and Stereotaxis Inc. (USA), Holm made decisive contributions towards the introduction of new, innovative products and technologies that quickly established themselves in clinical routines in the field of cardiology and electrophysiology (3-D electro-anatomical mapping of heart chambers, drug eluting stents and robot controls of interventional therapeutic heart catheters).

Besides his role as Venture Partner at PVP, Holm is the CEO of a cardiology focused early-stage medical device company in Germany and Belgium, is engaged as mentor and jury member of EIT Health and EIC Accelerator programs and serves as Chairman of the Board and board member for the medical device companies MedBeat Sweden and CathVision (Denmark), respectively.

Magnus Holm has a Master of Science in Biomedical Technology from the University of Linköping and a PhD in Clinical Cardiology from the University of Lund (Sweden).

Portfolio CBF-1

• Miracor Medical SA

Dr. Tim Hiddemann

Partner LIIDO Fonds

• Founder & Managing Director of international Research Reagent eCommerce company (15+ years)
• Co-founder of leading Life Science advertising & business intelligence player
• Advisor for leading Laboratory IoT company
  (7+ years)
• Strong spike in Digital Sales, Software Development, PhD in entrepreneurship

Jörg Hoffmann

Partner LIIDO Fonds

• Former CEO of multi-national Lab Infrastructure player (100m+ EUR)
• CEO of Labforward (LES-Software Company)
• 20+ years of international C-level management expertise
• Business Advisor for Shared Laboratory company (500m+ assets under management)
• Strong spike in B2B sales & international market entry

Simone Schöpp

Director Finance

Simone Schöpp joined Peppermint VenturePartners in January 2015. She supports our portfolio companies with her experiences in controlling and in the healthcare sector.

Prior to Peppermint she worked as Senior Financial Analyst with a pharmaceutical Contract Research Organisation first in Berlin and later in the US. Simone holds a Diploma in Business Administration from the HTW in Berlin.

Before and during her studies she gained professional experience in the research and in the finance department of an innovative biotech start-up, giving her a comprehensive understanding of the industry.

Henriette Braun

Executive Assistant

Henriette Braun has been working as the Assistant to the Managing Directors of PVP since December 2012.

Previously, she worked for several years as an executive assistant in the logistics field and as a scientific project team member in an environmental engineering firm.

Henriette holds a Diploma in Business Administration with a specialization in the fields of Environmental Management and Management of Small to Medium-Size Enterprises (SMEs) from the HTW in Berlin.

Stephanie Schlappa

Project Manager

Stephanie Schlappa is working as a project manager for Peppermint VenturePartners since 2022.

She is currently finishing her PhD at the University of Potsdam. She is working on the inline monitoring of emulsion polymerization processes regarding absorption and scattering properties and particle characteristics for industrially relevant processes.

Prior to her PhD Stephanie graduated in Applied Chemistry from TH Cologne in 2018.